R01MH134045

Neural circuit-specific mechanisms of ketamine's effect on anhedonia and anxiety in depression using ultra-high field 7-Tesla MRI.

Depression is a devastating public health problem, yet the pathophysiological mechanisms underlying distinct aspects of the disorder remain largely unknown. Convergent evidence from animal and human studies have strongly implicated functional perturbations in the subgenual anterior cingulate cortex (SGACC) in depression. However, it is not known how dysfunction within specific sub-circuits of this heterogeneous structure map to specific depression-related symptom domains.

This gap in knowledge concerning the pathophysiology of depression is a major impediment to the advancement of diagnostic and therapeutic approaches to this disabling disorder. To address this gap, we propose a rigorous translational neuroscience study to define the distinct circuit-specific mechanisms of anhedonia and anxiety in humans with depression, building upon work in non-human primates, and converging human evidence from our laboratories.

In marmosets, selective over-activation of Brodmann Area 25 (BA25) within the SGACC via glutamate re-uptake inhibition causally leads to deficits in anticipatory arousal – an established analogue of anhedonia in humans. Critically, these behavioral deficits are selectively reversed by peripheral administration of the glutamate NMDA receptor antagonist ketamine.

Pilot work from our laboratory shows a remarkable degree of inter-species convergence, pointing towards conservation of a glutamate-sensitive sub-circuit within the SGACC/BA25 that controls hedonic responses to environmental stimuli. We show that the SGACC/BA25 is specifically overactive in response to positive (but not negative) incentives in individuals with Major Depressive Disorder (MDD) compared to unaffected health control (HC) individuals.

We also show that the magnitude of activation specifically within BA25 (but not more rostral prelimbic area 32 [PL32]) is positively associated with degree of self-reported anhedonia, as predicted by primate work. Finally, we show that a single intravenous infusion of ketamine specifically reverses overactivation of the BA25 to positive stimuli; the degree of reduction in BA25 following ketamine correlated with improved self-reported anhedonia (but not anxiety), as predicted by primate work.

The overall goal of the proposed work is to define the distinct circuit-specific mechanisms of anhedonia and anxiety in humans with depression. To complete Aim 1, we will enroll N=60 medication-free adults with MDD and N=60 HC adults. All individuals will undergo clinical and behavioral assessment of anhedonia, anxiety, and other depression-relevant domains and both resting-state and task-based acquisitions with a validated reward task using ultra-high-field 7-Tesla (7T) MRI.

To complete Aim 2, the N=60 medication-free adults with MDD from Aim 1 will be randomized to either a single IV infusion of 0.5 mg/kg racemic ketamine (KET) or placebo (PBO, saline) and undergo repeated clinical and behavioral assessments and 7T MRI at 24 hours post-treatment. To complete Aim 3, all MDD participants from Aim 2 will undergo follow-up clinical and behavioral assessments and 7T MRI at 7 days post-treatment.

Participants will complete mobile digital health measures over the 7-day follow-up time, and for a total of 4 weeks from dosing.

Icahn School Of Medicine At Mount Sinai

NOT APPLICABLE

93.242 - Mental Health Research Grants

National Institute of Mental Health (NIMH) [HHS - NIH]

New York, New York 100296504 United States

Single Zip Code

Research Project Grant (Parent R01 Clinical Trial Required) (PA-20-183)

Amendment Since initial award the total obligations have increased 299% from $768,462 to $3,066,243.